Tryptophan immunoadsorption as escalation therapy for multiple sclerosis relapse - documentation of efficacy

• Conditions: Multiple sclerosis; G35

• Registration Number: DRKS00010099
• Lead Sponsor: Klinik für NeurologieKlinikum Lüdenscheid

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2015-12-31
• Study Start: 2016-02-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 147

Inclusion Criteria

acute MS relapse with indication for escalation therapy with immunoadsorption

Exclusion Criteria

Patient doesn´t agree to participate. Treating physician doesn´t want to participate in the investigation

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main outcome parameter for efficacy of immunoadsorption is change of acute ms relapse related disability. Clinical evaluation is performed before the first IA and after the last IA of the treatment series. Functional MS-related disability will be assessed with the EDSS (expanded disability status scale). In patients with optic neuritis also the best corrected visual acuity will be used.

Secondary Outcome Measures

Name	Time	Method
Tolerability and safety of immunoadsorption. IA treatments will be documented in CRF´s. Parameter for safety and tolerability are: blood pressure, vascular access, fibrinogen concentration, treated plasma volume, general condition of the patient.<br><br><br>